Identification and Prioritization of the Economic Impacts of Vaccines
Table 3
Overview ranking BWS, relevance, and data availability.
Economic impact (domain)
RIS (95% CI)
Relevance (%)
Data availability (%)
(1) Mortality (A)
13.96 (12.88–15.04)
17 (89.5%)
13 (68.4%)
(3) Healthcare expenditure (A)
12.76 (11.43–14.09)
15 (78.9%)
9 (47.4%)
(2) Morbidity (A)
12.69 (11.53–13.85)
19 (100%)
8 (42.1%)
(13) Behavior-related productivity (D)
8.07 (6.73–9.41)
14 (73.7%)
3 (15.8%)
(11) Risk reduction (C)
6.62 (4.64–8.59)
13 (68.4%)
2 (10.5%)
(9) Outbreak prevention costs (C)
6.52 (4.46–8.59)
16 (84.2%)
8 (42.1%)
(6) Outcome-related productivity (B)
6.35 (4.60–8.10)
16 (84.2%)
4 (21.1%)
(5) Care-related productivity (B)
6.05 (4.51–7.59)
17 (89.5%)
6 (31.6%)
(12) Economies of scale (C)
5.59 (3.57–7.60)
15 (78.9%)
5 (26.3%)
(8) Community health externalities (C)
4.15 (2.93–5.37)
17 (89.5%)
4 (21.1%)
(7) Impact on other diseases (C)
4.07 (2.54–5.61)
14 (73.7%)
2 (10.5%)
(10) Equity (C)
3.69 (1.93–5.45)
11 (57.9%)
3 (15.8%)
(4) School absenteeism (B)
3.04 (2.25–3.83)
17 (89.5%)
3 (15.8%)
(17) Impact on GDP (D)
2.44 (1.13–3.74)
8 (42.1%)
2 (10.5%)
(15) Employment in society (D)
1.72 (0.73–2.70)
8 (42.1%)
1 (5.2%)
(16) Impact on consumption behavior (D)
0.85 (0.00–3.75)
7 (36.8%)
0 (0.0%)
(14) Demographic dividend (D)
0.82 (0.34–1.31)
8 (41.2%)
3 (17.6%)
(18) Impact on tax revenues (D)
0.60 (0.13–1.07)
7 (35.3%)
1 (5.9%)
A: Health related benefits to vaccinated individuals. B: Short-term and long-term productivity gains. C: Community or health systems externalities. D: Broader economic indicators.
